CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 238 enrolled
Drug / intervention
Nicorandil +1 moredrug
Likely dose
Nicorandil 12mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03445728
NCT03445728Phase 4Completed

Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Chinese PLA General Hospital·interventional·Posted Feb 26, 2018·Updated Nov 24, 2021

In Brief

A Phase 4 clinical trial evaluating Nicorandil and Placebo for Myocardial Infarction and 2 related conditions. Completed, enrolled 238 participants across 1 site.

Detailed Summary

We compared the infarct size in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) treated by nicorandil before and after the reperfusion with those standard therapy treated by PCI

Study Details

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedFeb 26, 2018
Enrollment StartFeb 24, 2018
Primary CompletionJul 31, 2020
Study CompletionOct 1, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.3 years ago

Interventions

Nicorandildrug

After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h

Placeboother

After randomization, receive primary PCI and standard therapy, just like the intervension group also iv. just before ballooning or stenting, then keep ivgtt. up to 24h